ERBB2 and breast carcinoma: Recently, FDA-approved neratinib, a new HER2 inhibitor for the treatment of patients with metastatic HER2-positive breast cancer (ClinicalTrials.gov identifier: NCT01808573) (U.S.F.A.D.